Won’t you come on in?  How to favor lymphocyte infiltration in tumors

Matteo Bellone,1,3,* Arianna Calcinotto1,3,4 and Angelo Corti1,2,3

1Cellular Immunology Unit; San Raffaele Scientific Institute; Milan, Italy; 2Tumor Biology and Vascular Targeting Unit; San Raffaele Scientific Institute; Milan, Italy; 3Program of Immunology, Gene Therapy and Bio-Immunotherapy of Cancer (PIBIC); San Raffaele Scientific Institute; Milan, Italy; 4Università Vita-Salute San Raffaele; Milan, Italy

Keywords: tumor, T cells, immunotherapy, cell trafficking, endothelial cells

Abnormal tumor vasculature and endothelial cell anergy limit tumor/T-cell interactions. We have found that NGR-TNF, a tumor vasculature-homing derivative of TNF, selectively activates endothelial cells in neoplastic tissues and induces the release of chemokines that favor tumor infiltration by T cells, thereby enhancing the efficacy of active and adoptive immunotherapy.

One major hurdle that tumor-specific T cells must overcome to get in direct contact with their targets is crossing of the abnormal tumor vessel barrier and interstitium. Indeed, the tumor vasculature is disorganized, tortuous and leaker than normal vessels, and this may cause increased interstitial pressure, heterogeneous permeability and irregular blood flow. In addition, exposure to angiogenic factors [e.g., vascular endothelial growth factors (VEGF) and fibroblast growth factors (FGF)] causes downregulation of intracellular adhesion molecule-1/2 (ICAM-1/2), vascular cell adhesion molecule-1 (VCAM-1) and CD34 on endothelial cells (EC).1 Thus, leukocyte-endothelium interactions are diminished in tumors and effector T cells, regardless of being induced in vivo by vaccination or adoptively transferred, are impaired in their deployment at tumor sites where they get in direct contact with target tumor cells.

Tumor necrosis factor (TNF) is an inflammatory cytokine capable of inducing endothelial cell activation and of increasing vessel permeability. We have previously shown that targeted delivery of small amounts of TNF to tumor vessels is sufficient to increase their permeability, without causing toxic reactions.2 For example, this was achieved by coupling TNF with a peptide containing the Asn-Gly-Arg (NGR) motif, a ligand of an aminopeptidase N (CD13) isoform selectively expressed by EC in tumor vessels.3 Because of these properties this drug (originally developed by our group and called NGR-TNF) can increase the penetration of various chemotherapy agents in tumors.2 Thus, we hypothesized that pre-treatment of tumor-bearing subjects with NGR-TNF might favor lymphocyte infiltration in their neoplastic tissues.4

We have recently investigated this hypothesis in murine cancer models.5 We have found that administration of picogram doses of NGR-TNF to tumor-bearing mice induces, 2 h after injection, the upregulation VCAM-1 and ICAM-2 in EC, as well as the local release of several cytokines/chemokines involved in T cell activation and migration, including MCP-1/CCL-2, MCP-3/CCL-7, MIP-2, oncostatin-M and stem cell factor (SCF). This rapid and transient modification of the tumor microenvironment associates with tumor infiltration of fully activated endogenous or adoptively transferred cytotoxic T lymphocytes in transplanted models of melanoma and the transgenic adenocarcinoma of the mouse prostate (TRAMP) model of spontaneous prostate cancer (Fig. 1). Remarkably, NGR-TNF did not modify T cell distribution in the blood, spleen or kidney of tumor-bearing mice, highlighting the selective effects of NGR-TNF on tumor tissues.5

While the measured effects of NGR-TNF were short lasting, its beneficial effects on TIL persisted for days and the combination of NGR-TNF and adoptive immunotherapy increased the overall survival of tumor bearing mice with no evidence of toxic reactions.

Finally, we observed that NGR-TNF could also increase the efficacy of active immunotherapy (vaccination) either alone or in combination with chemotherapy.5 One explanation for these synergies is that the temporary reduction of the endothelial-barrier function induced by NGR-TNF might favor the penetration of both drug and lymphocytes in tumors, thereby increasing tumor debulking by chemotherapy and improving immunotherapy.4

Noteworthy, in all the experimental conditions tested a comparable dose of TNF was marginally or not active, supporting the hypothesis that targeted delivery of TNF to tumor vessels was crucial for the activity.

One limit of our study is that we have investigated the effects of NGR-TNF treatment only on T-cell infiltration in tumors. Different leukocyte populations can exploit the transient modifications of the tumor microenvironment induced by NGR-TNF (i.e., EC activation and release of chemokines). Thus, other leukocyte populations may be attracted within the tumor mass after NGR-TNF treatment,
which may contribute to the modification of the tumor microenvironment by making it more favorable for lymphocyte infiltration and effector functions.

Other strategies have been implemented to improve T-cell infiltration in tumors, based on the use of angiogenesis inhibitors like angiex, endostatin and angiostatin, or anti-VEGF reagents like soluble chimeric VEGF receptor (VEGFR), and anti-VEGF or VEGFR antibodies. These drugs transiently normalize the tumor vasculature, pruning away immature and leaky vessels and remodeling the remaining vasculature. As a result, the enhanced oncotic pressure gradient together with decreased interstitial fluid pressure gradient facilitate the delivery of oxygen, nutrients and also of chemotherapeutic agents into the tumor microenvironment. Anginex, endostatin and angiostatin can also overcome EC anergy preventing VCAM-1 and ICAM-1 downregulation, therefore promoting leukocyte infiltration in tumors. The mechanism by which anti-VEGF reagents favor T-cell infiltration in tumors has not yet been defined.

From a conceptual point of view these strategies are different from that proposed in our study, as they are based on the use of anti-angiogenic compounds that inhibit the formation of new blood vessels and promote vascular "normalization", whereas NGR-TNF is an inflammatory-vascular targeting agent that induces vascular "activation." Notably, these therapeutic approaches require markedly different doses of drugs and different schedules of administration, thus with potentially different toxic reactions. The observation that extremely low doses of NGR-TNF (picograms) are sufficient to induce local inflammation in murine tumors with no signs of systemic toxicity (the corresponding dose is well tolerated also in patients) makes NGR-TNF an attractive agent for the combination with immunotherapy. At this regard, it is remarkable that most of the effects induced by NGR-TNF on the vessels of murine tumors have been observed also in patients. This suggests that murine models of cancer are reliable predictors of the response to NGR-TNF in patients. Based on this assumption and on the data obtained with melanoma models reported herein, a Phase I/II clinical trial based on the combination of NGR-TNF with active immunotherapy has been recently started in melanoma patients.

Disclosure of Potential Conflicts of Interest
A.C. is the inventor of a patent on NGR-TNF.
5. Calcinotto A, Geoni M, Jachetti E, Curnis F, Mondino A, Parmiani G, et al. Targeting TNFα to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy. J Immunol 2012; 188:2687-94; PMID:22323546; http://dx.doi.org/10.4049/jimmuno.1101877.

6. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, et al. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J 2006; 20:621-30; PMID:16581970; http://dx.doi.org/10.1096/fj.05-4493com.

7. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006; 12:6808-16; PMID:17121902; http://dx.doi.org/10.1158/1078-0432.CCR-06-1558.

8. Shriml RK, Yu Z, Theoter MR, Chinnasamy D, Restifo NP, Rosenberg SA. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010; 70:6171-80; PMID:20631075; http://dx.doi.org/10.1158/0008-5472.CAN-10-0153.

9. Manning EA, Ullman JG, Leatherman JM, Asquith JM, Hansen TR, Armstrong TD, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res 2007; 13:3951-9; PMID:17606729; http://dx.doi.org/10.1158/1078-0432.CCR-07-0374.

10. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi.org/10.1126/science.1104819.